You are here: Industry Insights > MDD

News List

HMNC Brain Health Raises EUR 9 Million firstwordpharma
July 29, 2021
HMNC Brain Health (“HMNC” or the “Company”), a biotech company pioneering the development of personalized therapies in psychiatry powered by predictive companion diagnostics, today announced it has received an additional EUR 9 million EUR from its current
Novel pipeline agents to drive global major depressive disorder market: GlobalData expresspharma
April 08, 2021
The major depressive disorder (MDD) market is expected to grow from $3.97 billion in 2019 to $7.87 billion by 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 7.1 per cent, according to GlobalData.
EU approves expanded use of Janssen’s Spravato pharmatimes
February 09, 2021
The European Commission (EC) has approved the expanded use of Janssen’s Spravato for the rapid reduction of depressive symptoms in a psychiatric emergency, for adult patients with a moderate-to-severe episode of major depressive disorder (MDD).
Acadia pulls plug on pimavanserin for adjunctive MDD pharmatimes
July 24, 2020
Acadia Pharmaceuticals has terminated development of pimavanserin for major depressive disorder (MDD) after the drug failed to hit trials in this setting.
Anti-Inflammatory Add-On May Be Beneficial for Depression drugs
April 19, 2019
Anti-Inflammatory Add-On May Be Beneficial for Depression.
Allergan's rapastinel fails to hit key targets in depression trials pharmatimes
March 08, 2019
Allergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression.
Studies Look at Ways to Reduce Depressive Episodes in Obese drugs
March 06, 2019
For overweight adults with depression, daily multinutrient supplements and individual or group therapy sessions do not reduce major depressive disorder (MDD) episodes over one year...
“All-powerful Drug” of Allergan: Botox Pushed Clinical Trial, MDD Clinical Protocol Postponed PharmaSources/Zhulikou431
January 09, 2019
Phase III clinical trial of Allergan’s Botox for major depressive disorder (MDD) will be pushed to the second half of 2019 (H2 2019), said the spokesperson of the company recently.
Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder pharmafocusasia
January 07, 2019
Otsuka America, Inc., and Click Therapeutics, Inc., announce today that the companies have signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for .....
Increased funding and research could help address unmet mental health needs pharmafile
November 20, 2018
Unmet needs relating to mental health could be met through increasing funding and research, according to data analytics firm GlobalData.

Previous page 1 2 Next page